For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Exelixis Inc. (EXEL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -6 (−100…+100 Quality+Value blend) · Quality 66 · Value -65 · Sentiment 6 (timing only, not weighted) · Composite fair value $43.16 vs $55.97 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Exelixis Inc.
EXEL NASDAQExelixis Inc. is an oncology-focused biopharmaceutical company specializing in the discovery, development, and commercialization of targeted cancer therapies. Based in Alameda, California and founded in 1994, the company operates as a single business segment dedicated to difficult-to-treat cancers. Exelixis’ portfolio centers on cabozantinib, a multikinase inhibitor marketed in different formulations, which serves as its flagship medicine for various solid tumor indications. In addition, the company has brought to market other oncology and cardiovascular products, including COTELLIC and MINNEBRO, through partnerships with larger pharmaceutical firms. Exelixis runs a broad pipeline of small-molecule and biologic candidates, advancing internally discovered assets and externally sourced programs across multiple mechanisms of action. The company commercializes products directly in the United States and relies on strategic alliances to reach international markets, positioning Exelixis as a significant player in the global market for innovative cancer treatments.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.78
Total Equity: $2.16B
Shares: 281,863,000
Total Debt: $0.00
Cash: $482.49M
EBITDA: $901.25M
Total Debt: $0.00
Cash: $482.49M
Revenue: $2.32B
Revenue: $2.32B
Revenue: $2.32B
Total Equity: $2.16B
Tax Rate: N/A
Equity: $2.16B
Total Debt: $0.00
Cash: $482.49M
Current Liabilities: $405.64M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $2.16B
Shares: 281,863,000
Shares: 281,863,000
CapEx: -$8.43M
Shares: 281,863,000
Stock Price: $55.97
Net Income: $782.57M
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 7:24pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| Cost of Revenue | $52.9M | $57.9M | $72.5M | $76.2M | $83.7M |
| Gross Profit | $1.4B | $1.6B | $1.8B | $2.1B | $2.2B |
| Operating Expenses | $1.1B | $1.4B | $1.6B | $1.5B | $1.4B |
| Operating Income | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Net Income | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| EBITDA | $300.3M | $222.4M | $196.6M | $633.4M | $901.2M |
| EPS | $0.73 | $0.57 | $0.65 | $1.80 | $2.88 |
| EPS (Diluted) | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 6:57pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $647.2M | $501.2M | $263.0M | $217.4M | $482.5M |
| Total Current Assets | $1.8B | $1.6B | $1.3B | $1.5B | $1.4B |
| Total Assets | $2.6B | $3.1B | $2.9B | $2.9B | $2.8B |
| Current Liabilities | $337.6M | $324.4M | $394.3M | $403.8M | $405.6M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $405.6M | $583.1M | $678.4M | $703.5M | $683.1M |
| Total Equity | $2.2B | $2.5B | $2.3B | $2.2B | $2.2B |
| Retained Earnings | -$216.5M | -$34.2M | -$173.4M | -$98.6M | -$76.8M |
Cash Flow (Annual)
Last updated: Jul 30, 2026 7:24pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $400.8M | $362.6M | $333.3M | $700.0M | $884.3M |
| Capital Expenditure | -$64.2M | -$27.7M | -$40.5M | -$28.4M | -$8.4M |
| Free Cash Flow | $336.6M | $334.9M | $292.9M | $671.5M | $875.8M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$550.4M | -$652.0M | -$947.5M |
| Net Change in Cash | $343.1M | -$161.2M | -$239.7M | -$45.6M | $265.1M |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 7:24pm (24d ago)| Metric | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue Growth | +12.3% | +13.6% | +18.5% | +7.0% |
| Gross Profit Growth | +12.4% | +13.2% | +19.0% | +6.9% |
| Operating Income Growth | -29.7% | -15.2% | +253.8% | +44.3% |
| Net Income Growth | -21.1% | +14.0% | +150.9% | +50.1% |
| EBITDA Growth | -26.0% | -11.6% | +222.2% | +42.3% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:51Recovery pays +10%; another quarter like the worst recent one costs 19%. Ratio 0.5:1.
| Case | Growth | Margin | Fair value | vs price ($55.97) |
|---|---|---|---|---|
| Bull — recovery | +15% | 35.0% | $61.39 | +10% |
| Base — stabilizes | +10% | 35.0% | $52.44 | -6% |
| Bear — keeps slipping | +5% | 30.0% | $38.84 | -31% |
| Stress — last quarter repeats | +6% | 35.0% | $45.44 | -19% |
Narrative Economics
market-narrative step).
Claude Reading
Looking at the raw trajectory first: revenue has moved from $539M (Q3 2024) to $611M (Q1 2026), a 13% climb over six quarters, but the sequential deltas are decelerating — $597.8M → $598.7M → $610.8M is essentially flat in the last two prints. Net income is noisier: $210.5M this quarter versus $244.5M prior (down 14% sequentially) and margin compressed from 40.8% to 34.5%. The Q2 2024 print of $637M with $226M NI is actually the highest revenue quarter in the file — meaning on a strict YoY basis, the most recent quarter is only ~7% below that peak, not accelerating. The "94% earnings CAGR" is a base-effect artifact from a depressed 2023 ($208M NI) and does not describe forward economics. Trailing FCF of $876M against a $14.07B market cap gives a 6.2% FCF yield — respectable but not screamingly cheap for a single-product oncology name facing composition-of-matter expiry considerations.
The synthesis calls fair value $41–47 versus $56, roughly 16–27% downside. I think that's directionally right but the magnitude is aggressive. Backing into it: $876M FCF × a 15x multiple (reasonable for a de-risked but patent-exposed cash cow with zero debt and $482M cash) = $13.1B EV, or ~$52/share. Push the multiple to 17x for the clean balance sheet and ROIC of 41%, and you get ~$59. So my honest fair value band is $50–60, with $56 sitting right in the middle. The synthesis and the market-forces model are anchored too heavily on the patent-cliff binary framing; the pre-flight and narrative models are closer to reality in calling this a moderate-growth steady compounder. There's an internal contradiction in the prior outputs: "accelerating quarterly trend" (Revenue Confidence) and "peak-earnings" (Market Forces) cannot both be true, and the tape supports neither cleanly — it supports "plateauing at a high level."
The contrarian bear case is real and under-modeled by the bulls: cabozantinib IP dynamics start biting later this decade, zanzalintinib (the designated successor) still needs to prove itself in pivotal readouts, and the 96% gross margin plus 38% operating margin cannot expand further — all future EPS growth must come from top-line, which just decelerated to 7% YoY. Insider activity is genuinely neutral-to-slightly-negative: two small sales against a wall of RSU awards is boilerplate, but there's no insider buying at $56 despite the stock having rallied 65% off lows — insiders who know the pipeline timeline are not stepping up. The contrarian bull case is the acquisition option: zero debt, $482M cash, $875M FCF, dominant RCC franchise — this is exactly the kind of asset large pharma buys at a 30–40% premium when their own patent cliffs loom, and that optionality is not in a DCF.
Net: I dissent partially from the synthesis. Fair-value-priced, not overvalued. The $46.82 signal-adjusted target implies a de-rating to ~10x FCF that only makes sense if you're confident cabozantinib revenue rolls over hard by 2027, and the Q1 2026 print of $611M growing 13% off the trough doesn't support that timeline yet. But I also dissent from any "undervalued, buy here" read — you're paying a 20x P/E and 6.8x sales for a business whose next two years of earnings look flat-to-modestly-up, with a real terminal-value question mark. This is a hold-if-you-own-it, wait-for-$48-if-you-don't situation. The right catalyst to force a re-underwriting is zanzalintinib Phase 3 readouts and any CRC/prostate label expansion data — until then, position sizing should reflect the binary nature of the 2027+ outlook. The market-forces model's "binary bet" framing is overstated for a company generating $875M in annual FCF today, but its underlying concern about a lack of compounding runway is legitimate.
GPT Reading
Exelixis looks much more like a high-quality pharma cash machine than a speculative biotech, and the raw numbers are better than the “fully priced” label suggests. Revenue has climbed from $1.43B in 2021 to $2.32B in 2026, a 62% increase in five years, but the bigger story is margin expansion: operating income went from $287M to $872M and net income from $231M to $783M. That is not financial engineering; it is visible in the quarterlies as net margin stepped up from 21.9% in Sep-2024 to 24.7%, 28.7%, 32.5%, 32.4%, 40.8%, then 34.5% most recently. Even if I normalize away the 40.8% quarter as unusually strong, this is now a business earning roughly one-third of revenue as profit and converting that into cash. With $875.8M of free cash flow on $782.6M of net income and essentially no debt, this is one of the cleaner earnings streams in the sector.
At $55.97, the market cap is $14.07B, which is about 18x trailing net income and about 16x trailing free cash flow using the reported $875.8M. For a debt-free oncology company with 96% gross margins, 37.6% operating margins, 41% ROIC, and still-positive top-line growth, that does not strike me as expensive. The latest four quarters sum to about $2.36B of revenue and $832M of net income, so the business is still growing into the multiple rather than relying on a rebound. The sequential revenue trend is also firmer than the bear case usually allows: after dipping from $637M in Jun-2024 to $540M in Sep-2024, revenue has rebuilt to $567M, $555M, $568M, $598M, and $611M. This is not a franchise already rolling over. The market seems to be valuing Exelixis as if peak earnings are near and decline is the base case; the actual data still show durable demand and improving profitability.
What stands out to me is the mismatch between quality and valuation. A P/E around 20 for a low-capex, net-cash business would be pedestrian even for an industrial compounder; here you are getting pharma-like margins and biotech optionality on top. Price-to-sales at 6.8x sounds rich until you remember the company keeps more than a third of each sales dollar as net income. On an earnings power basis, the multiple is much less demanding than the headline P/S or P/B. The balance sheet also matters: $482.5M of cash, zero debt, and a current ratio of 3.6 mean the company does not need capital markets and can fund pipeline work internally. For a sector where dilution and leverage often destroy equity value, that deserves a premium, not a discount. I think fair value is at least in the low-to-mid $60s on current earnings, with upside beyond that if the franchise proves it can hold revenue above $2.4B annualized.
The best argument against this view is straightforward and serious: this is still a concentrated oncology story, and the market may be correctly refusing to capitalize current margins as durable. Annual revenue growth has already slowed to single digits recently, with the latest YoY revenue increase only 7%, while the stock has rallied sharply. Earnings are outgrowing revenue mainly through margin expansion, which is harder to repeat indefinitely than volume growth. If investors believe the core franchise is within a few years of plateauing and eventual erosion, then 15x EV/EBITDA and 20x earnings are not cheap at all; they are the right multiples for a business near peak profitability. The very high ROE and ROIC can also be read less as evidence of an underappreciated compounder and more as a sign that the company has harvested the easy economics from a mature asset base. In that framing, the model-derived fair values in the low-to-mid $40s are basically saying: don’t annualize the best years.
What would change my mind is not a theoretical patent-cliff narrative but actual erosion in the operating data. If quarterly revenue slips back below $550M for multiple quarters, or if net margin falls from the low-30s back toward the low-20s without a corresponding pipeline investment explanation, I would assume the franchise has started its fade and re-rate the stock downward quickly. Likewise, if the next annual free cash flow drops materially below $700M despite similar revenue, that would tell me the current cash machine is less durable than it appears. Absent that, I think the market is paying a fair-to-reasonable multiple for a business whose current earnings quality is stronger than the skepticism around it.
Grok Reading
The raw numbers describe a business that has already completed its most dramatic transformation. Exelixis grew revenue from $1.83B in 2023 to $2.32B in the latest fiscal year while expanding operating income from $171M to $872M—an operating-margin leap from roughly 9% to 38% that produced a 94% earnings CAGR and free cash flow of $876M on essentially zero capital intensity. Quarterly run-rate is still grinding higher ($555M → $611M over the last five reported periods), net margins have stabilized in the low-to-mid 30s, and the balance sheet carries no debt against $483M cash and a 3.6 current ratio. At a 20× trailing P/E, 15× EV/EBITDA and a 6.2% FCF yield, the stock does not look optically expensive for a high-ROIC (41%) oncology franchise. The catch is that virtually all of the multiple expansion and margin capture has already occurred; recent revenue growth has slowed to 7% year-over-year, gross margin is already 96%, and further operating leverage is limited. What remains is a single-product cash cow whose durability is now the only question that matters.
The valuation models’ $41–47 fair-value range versus the $56 print is directionally correct once the product cycle is placed in time. Cabozantinib is approaching the 2026–2028 patent window; the market is therefore paying a modest narrative premium (roughly 15–20%) for label-expansion longevity and pipeline optionality that has not yet shown up in the P&L. Insider activity is noise—routine awards and small sales—while the “accelerating” quarterly revenue tag is real but modest in absolute dollars. In short, the fundamentals are excellent, the multiple is no longer cheap relative to remaining duration, and the stock has already discounted a soft landing rather than a cliff.
The strongest counter-argument is straightforward: a zero-debt compounder throwing off nearly $900M of annual free cash flow at 20× earnings with 50% recent earnings growth and sector-beating returns on capital is rarely a short. If cabozantinib holds share longer than expected through combinations, or if any pipeline asset or M&A bid materializes, the current price becomes a bargain and the FCF simply accumulates for buybacks or a special dividend. That bull case is coherent; I simply assign lower probability to multi-year franchise extension than the market currently does, given competitive intensity in RCC/HCC and the absence of a clear next growth driver in the reported numbers.
I would reverse to a clear buy if the next two quarters show revenue re-accelerating above 12% while management demonstrates tangible patent-life extension or a late-stage pipeline win that diversifies the top line; conversely, any sequential revenue decline or guidance cut tied to competitive share loss would confirm the overvaluation thesis and push fair value toward the low $40s.
Big-3 Panel — where each AI stands
Claude — Second Response · fairly valued held
VERDICT: Fairly valued at $56 within a $50-61 band; GPT's margin-quality argument nudges my ceiling up ~$1 but the 7% YoY decel and unresolved 2027+ terminal value still preclude a buy above $50.
GPT's strongest push is on the operating data: five sequential quarterly revenue prints rebuilding from $540M to $611M, net margin stepped from 22% to a stabilized low-30s, and $876M FCF on zero debt. That is a real rebuttal to "peak earnings" framing, and it made me re-check my own decel claim. But when I actually run it: $598.7M → $610.8M is 2% sequential, and YoY the most recent quarter is 7-8% — GPT's own number. That's rebuilding, not accelerating, and it doesn't get you to the low-$60s fair value without capitalizing the 40.8%-margin quarter as normal, which GPT explicitly says he'd normalize away. The math cuts against his conclusion more than he acknowledges: at $832M normalized TTM NI and 18x (his own multiple), you get ~$15B market cap or ~$60/share — the top of my band, not a distinct undervalued call. So GPT moved my ceiling maybe a dollar; he didn't move my center.
Grok is closer to my read but lands 8-10% lower ($45-48 vs my $50-60). His argument rests on assigning higher probability to the 2026-2028 patent window biting. That's a probability assertion, not a data point — and the Q1 2026 print showing the franchise still growing 7% YoY is evidence *against* imminent erosion, not for it. Grok concedes the bull case is "coherent" and rests his bear call on subjective probability weighting. I won't drift there without a catalyst.
What genuinely nagged at me from both colleagues: I may have under-weighted the balance-sheet quality premium. Zero debt, $483M cash, 3.6 current ratio, 41% ROIC, and $876M FCF is a rarer profile than my 15-17x multiple assumed. Fair to nudge the top of my band to $61 rather than $60. But the core call holds: no margin of safety at $56, no insider buying into the rally, and the terminal-value question is unresolved until zanzalintinib reads out. Hold, don't chase.
GPT — Second Response · fairly valued changed direction
VERDICT: Fairly valued around $56; reasonable value band is roughly $50-$60, with a more attractive entry below ~$50 unless pipeline de-risking justifies a move into the low $60s.
Claude’s framing moved me more than Grok’s: the key point is not “cheap quality” but “plateauing at a high level.” I underweighted how much of the earnings story was margin capture from a depressed 2023 base rather than a durable new growth slope. The recent operating data are still good, but they are no longer obviously compounding fast enough to justify calling $56 clearly undervalued on a single-franchise asset. Specifically, the last two quarters being essentially flat on revenue ($598.7M to $610.8M) while net margin fell from 40.8% to 34.5% weakens my prior emphasis on an improving earnings run-rate; it suggests normalization around a strong plateau, not an upward staircase. Claude’s 15x–17x FCF framework also better fits the facts than my low-$60s anchor: on $876M FCF, that gets you roughly $52–59 before giving much credit for pipeline optionality.
What did not move me is the stronger overvaluation case. Grok is right that patent-duration risk dominates terminal value, but the implied fair value in the mid-$40s still feels too punitive absent actual revenue rollover. A debt-free company with ~$876M FCF, ~38% operating margins, and no sign yet of hard franchise erosion should not trade like a melting-ice-cube today. The real issue is that I was too quick to convert current quality into present undervaluation. The clean balance sheet, cash generation, and possible strategic value remain meaningful offsets, but they create a hold/fair-value setup rather than a decisive bargain. So I’m revising from “undervalued” to “fairly valued,” with a bias to buy only on a pullback or on concrete de-risking of the post-cabozantinib runway.
Grok — Second Response · fairly valued changed direction
VERDICT: Fairly valued at $56 inside a $50–60 band; patent risk real but not yet forcing a sub-$50 multiple
Claude’s FCF-multiple arithmetic specifically moved me. Applying a clean 15–17× to the reported $876 M free-cash-flow run-rate produces $52–59 per share once net cash is added; that range sits far closer to the $56 print than my original $41–47 band, which had over-weighted an immediate patent-cliff de-rating. The sequential tape Claude cites—revenue rebuilding to $611 M and holding a high plateau rather than rolling over—further undercuts the assumption that 2026–28 composition-of-matter risk must be fully capitalized today. GPT’s push to $62–68, by contrast, fails on the same numbers: 7 % trailing revenue growth, already-peak 96 % gross and mid-30s net margins, and zero diversification leave little room to expand the multiple further, so the quality premium is already reflected.
I therefore drop the “modestly overvalued” label. The stock is fairly valued inside a $50–60 corridor; the acquisition optionality Claude notes is real but not yet priced as a free call, and zanzalintinib read-outs remain the only catalyst that could justify a higher band. Until those data arrive or the shares slip below $50, the risk/reward is balanced rather than asymmetric.
Advanced Analysis Forensic deep-dive · separate lenses
Exelixis has moved from a low-teens operating margin business in 2021-2023 into a genuinely profitable one: revenue up from $1.43B to $2.32B, operating margin expanded from 20% to 37.6%, net income tripling from $231M to $783M, and FCF rising from $337M to $876M. Gross margin sits at a biotech-typical 96%+, and the operating leverage is the real story - fixed R&D and SG&A being covered by a growing Cabometyx-anchored top line. Altman Z of 14.58 and net cash of $1.06B mean survival is not a question.
Verify before trusting this (5)
- Cabometyx revenue concentration and patent/exclusivity timeline
- Pipeline depth beyond cabozantinib (zanzalintinib and others) and Phase 3 readouts
- Whether the 2025-2026 margin jump reflects sustainable operating leverage or one-time items (milestones, tax)
- Buyback authorization remaining and pace vs. SBC going forward
- R&D spend trajectory - is opex discipline sustainable or being under-invested?
The e2e synthesis pegs composite FV at $41.16 and signal-adjusted FV at $46.82 against a $55.97 price, implying roughly -16% to -26% downside on the central cases. The DCF at $50.87 is the friendliest read and still sits below the market; the EPV floor at $21.75 confirms that a large chunk of today's cap is priced on continued growth, not steady-state cash. Earnings quality is high (score 3), so no haircut is warranted - but that also means the fair-value numbers already reflect the clean earnings, leaving little hidden value to unlock. Company quality is Strong (66), which justifies pushing deserved value toward the upper end of the DCF, call it ~$48-51. Even at $51 that is roughly 9% below spot; at the signal-adjusted $46.82 the gap is ~-16%. The market appears to already credit cabozantinib label expansion, pipeline optionality, and continued buybacks. To justify $56 you need the bull case (durable franchise extension, successful pipeline, minimal checkpoint-inhibitor erosion) to largely play out - a plausible but not discounted outcome. This is a good business at a full price, not a mispricing.
Verify before trusting this (4)
- Cabozantinib revenue concentration and payer/price trends in RCC and HCC
- Pipeline readouts (zanzalintinib and next-gen assets) and probability-weighted contribution to FV
- Guidance on R&D reinvestment vs buyback pace - affects per-share deserved value
- Any label-extension or combination-trial data that would shift the DCF terminal assumptions
The macro tape is genuinely hostile right now - VIX above the 97th percentile, S&P rolling over, 10y at 4.61%, market PE stretched at 26.2 - but EXEL's 0.42 beta and defensive healthcare/oncology profile mute most of that pressure. Biotech with recurring cabozantinib cash flow is exactly the kind of name that gets bid as a relative safe-haven when growth and story stocks get marked down. So the market-wide headwind lands only lightly here. The narrative is a moderate-intensity, moderate-durability steady-compounder story with low cult coefficient - meaning there is no euphoria to unwind and no crowded long to puke. The bull case (label expansion, combos, pipeline optionality) and bear case (checkpoint-inhibitor competition, pricing pressure, no differentiated next-gen asset) are both well-known and roughly balanced; the stock carries only a modest premium to fundamentals, suggesting sentiment is neither running ahead nor collapsing. Momentum is constructive - a 12.6% CAGR and +22pp over three years - though the recent 7% pace is a mild deceleration. News flow in the window is empty for this ticker (the EXE headline is a different company), so there is no fresh catalyst pushing either way. Net: a small headwind from the stressed tape offset by defensive positioning and a stable narrative. Balanced, leaning very slightly negative on timing only.
Verify before trusting this (4)
- Any competitive readout in RCC/HCC from checkpoint-inhibitor combos that could crack the cabozantinib narrative
- Pipeline catalysts (zanzalintinib and earlier-stage assets) that could shift the story from steady-compounder to growth reacceleration
- Analyst target revisions and consensus splits post next earnings - direction of tone change matters more than level
- Whether the risk-off regime persists or resolves; a VIX unwind would remove the mild defensive bid
This lens hasn't been run for this ticker yet.
When we made this prediction on Jul 31, 2026, EXEL was $55.97. We expect it to be $50.80 by Jan 2027, and we consider it great value under $42.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Jul 31, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.